At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 7 enrolled
Drug / intervention
Lenvatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic RCC
In Brief
A Phase 1 clinical trial evaluating Lenvatinib and Everolimus for Carcinoma, Renal Cell. Completed, enrolled 7 participants across 3 sites.
Detailed Summary
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedMay 27, 2015
Enrollment StartJul 1, 2015
Primary CompletionMay 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.1 years ago
Interventions
Lenvatinibdrug
Everolimusdrug